Do analysts prefer STTK or MESO?

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 61.74%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Shattuck Labs 1 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is STTK or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Mesoblast N/A N/A N/A

Does the media refer more to STTK or MESO?

In the previous week, Mesoblast had 7 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Mesoblast and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Mesoblast's score of 0.21 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 2 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STTK or VERA more profitable?

Shattuck Labs' return on equity of -43.57% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Vera Therapeutics N/A -84.13% -66.79%

Does the media favor STTK or VERA?

In the previous week, Vera Therapeutics had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 6 mentions for Vera Therapeutics and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Vera Therapeutics' score of 0.55 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STTK or SLS more profitable?

SELLAS Life Sciences Group's return on equity of -35.91% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% SELLAS Life Sciences Group N/A -35.91% -33.34%

Does the media refer more to STTK or SLS?

In the previous week, SELLAS Life Sciences Group had 9 more articles in the media than Shattuck Labs. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat SELLAS Life Sciences Group's score of 0.60 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SELLAS Life Sciences Group 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is BHVN or STTK more profitable?

Shattuck Labs' return on equity of -43.57% beat Biohaven's return on equity. Company Net Margins Return on Equity Return on Assets Biohaven N/A -1,328.94% -138.27% Shattuck Labs N/A -43.57% -40.90%

Does the media prefer BHVN or STTK?

In the previous week, Biohaven had 14 more articles in the media than Shattuck Labs. MarketBeat recorded 16 mentions for Biohaven and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Biohaven's score of -0.07 indicating that Shattuck Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STTK or SEPN more profitable?

Shattuck Labs has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Shattuck Labs' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Septerna -24.51% -9.57% -6.28%

Does the media refer more to STTK or SEPN?

In the previous week, Septerna had 5 more articles in the media than Shattuck Labs. MarketBeat recorded 7 mentions for Septerna and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Septerna's score of 1.22 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 4 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Shattuck Labs (STTK) Competitors

$7.90 +0.37 (+4.91%)

Closing price 04:00 PM Eastern

Extended Trading

$7.90 +0.00 (+0.03%)

As of 04:34 PM Eastern

Compare

STTK vs. MESO, VERA, SLS, BHVN, and SEPN

Should you buy Shattuck Labs stock or one of its competitors? Shattuck Labs's main competitors and comparable companies include Mesoblast (MESO), Vera Therapeutics (VERA), SELLAS Life Sciences Group (SLS), Biohaven (BHVN), and Septerna (SEPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Shattuck Labs compare to Mesoblast?

Shattuck Labs (NASDAQ:STTK) and Mesoblast (NASDAQ:MESO) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 61.74%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Shattuck Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Shattuck Labs has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	792.87	-$48.81M	-$0.51	N/A
Mesoblast	$17.20M	125.65	-$102.14M	-$0.28	N/A

Mesoblast's return on equity of 0.00% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Mesoblast	N/A	N/A	N/A

In the previous week, Mesoblast had 7 more articles in the media than Shattuck Labs. MarketBeat recorded 9 mentions for Mesoblast and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Mesoblast's score of 0.21 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	2 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Shattuck Labs beats Mesoblast on 9 of the 16 factors compared between the two stocks.

How does Shattuck Labs compare to Vera Therapeutics?

Shattuck Labs (NASDAQ:STTK) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Shattuck Labs has higher revenue and earnings than Vera Therapeutics. Shattuck Labs is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	792.87	-$48.81M	-$0.51	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Shattuck Labs has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 61.74%. Vera Therapeutics has a consensus target price of $81.15, suggesting a potential upside of 140.67%. Given Vera Therapeutics' higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Shattuck Labs' return on equity of -43.57% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Vera Therapeutics	N/A	-84.13%	-66.79%

In the previous week, Vera Therapeutics had 4 more articles in the media than Shattuck Labs. MarketBeat recorded 6 mentions for Vera Therapeutics and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Vera Therapeutics' score of 0.55 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Shattuck Labs beats Vera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Shattuck Labs compare to SELLAS Life Sciences Group?

Shattuck Labs (NASDAQ:STTK) and SELLAS Life Sciences Group (NASDAQ:SLS) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

Shattuck Labs presently has a consensus price target of $12.78, indicating a potential upside of 61.74%. SELLAS Life Sciences Group has a consensus price target of $10.00, indicating a potential downside of 30.22%. Given Shattuck Labs' stronger consensus rating and higher probable upside, equities analysts clearly believe Shattuck Labs is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SELLAS Life Sciences Group has lower revenue, but higher earnings than Shattuck Labs. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	792.87	-$48.81M	-$0.51	N/A
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.21	N/A

In the previous week, SELLAS Life Sciences Group had 9 more articles in the media than Shattuck Labs. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat SELLAS Life Sciences Group's score of 0.60 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SELLAS Life Sciences Group	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

SELLAS Life Sciences Group's return on equity of -35.91% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
SELLAS Life Sciences Group	N/A	-35.91%	-33.34%

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, SELLAS Life Sciences Group has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market.

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 1.3% of SELLAS Life Sciences Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Shattuck Labs beats SELLAS Life Sciences Group on 9 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Biohaven?

Biohaven (NYSE:BHVN) and Shattuck Labs (NASDAQ:STTK) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Biohaven currently has a consensus price target of $21.75, suggesting a potential upside of 59.10%. Shattuck Labs has a consensus price target of $12.78, suggesting a potential upside of 61.74%. Given Shattuck Labs' stronger consensus rating and higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	2 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.65
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

In the previous week, Biohaven had 14 more articles in the media than Shattuck Labs. MarketBeat recorded 16 mentions for Biohaven and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Biohaven's score of -0.07 indicating that Shattuck Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs' return on equity of -43.57% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-1,328.94%	-138.27%
Shattuck Labs	N/A	-43.57%	-40.90%

Biohaven has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 58.7% of Shattuck Labs shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 8.8% of Shattuck Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Shattuck Labs has higher revenue and earnings than Biohaven. Shattuck Labs is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$738.82M	-$4.64	N/A
Shattuck Labs	$1M	792.87	-$48.81M	-$0.51	N/A

Summary

Shattuck Labs beats Biohaven on 9 of the 15 factors compared between the two stocks.

How does Shattuck Labs compare to Septerna?

Shattuck Labs (NASDAQ:STTK) and Septerna (NASDAQ:SEPN) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 61.74%. Septerna has a consensus target price of $52.44, suggesting a potential upside of 29.43%. Given Shattuck Labs' stronger consensus rating and higher possible upside, research analysts plainly believe Shattuck Labs is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Shattuck Labs has higher earnings, but lower revenue than Septerna. Septerna is trading at a lower price-to-earnings ratio than Shattuck Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	792.87	-$48.81M	-$0.51	N/A
Septerna	$98.88M	19.13	-$48.88M	-$0.54	N/A

In the previous week, Septerna had 5 more articles in the media than Shattuck Labs. MarketBeat recorded 7 mentions for Septerna and 2 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.40 beat Septerna's score of 1.22 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Shattuck Labs has a net margin of 0.00% compared to Septerna's net margin of -24.51%. Septerna's return on equity of -9.57% beat Shattuck Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Septerna	-24.51%	-9.57%	-6.28%

Shattuck Labs has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market. Comparatively, Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market.

58.7% of Shattuck Labs shares are held by institutional investors. 8.8% of Shattuck Labs shares are held by insiders. Comparatively, 5.8% of Septerna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Shattuck Labs beats Septerna on 11 of the 16 factors compared between the two stocks.

Get Shattuck Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STTK vs. The Competition

Export

Metric	Shattuck Labs	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$792.87M	$3.99B	$7.30B	$12.71B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-15.49	11.76	271.39	24.11
Price / Sales	792.87	1,296.80	604.56	77.78
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	6.08	17.27	11.18	6.40
Net Income	-$48.81M	-$22.72M	$3.46B	$348.28M
7 Day Performance	6.90%	2.83%	1.97%	0.95%
1 Month Performance	6.33%	9.67%	7.30%	5.15%
1 Year Performance	722.92%	54.74%	24.74%	16.18%

Shattuck Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STTK Shattuck Labs	3.7833 of 5 stars	$7.90 +4.9%	$12.78 +61.7%	+684.4%	$792.87M	$1M	N/A	100	Positive News Analyst Forecast High Trading Volume
MESO Mesoblast	0.3824 of 5 stars	$16.92 +1.4%	N/A	+7.5%	$2.20B	$65.38M	N/A	80	News Coverage Positive News
VERA Vera Therapeutics	3.0988 of 5 stars	$30.29 -4.1%	$83.85 +176.8%	+43.0%	$2.17B	N/A	N/A	40
SLS SELLAS Life Sciences Group	0.829 of 5 stars	$11.05 +0.1%	$10.00 -9.5%	+709.4%	$2.17B	N/A	N/A	10	Positive News Options Volume Gap Up
BHVN Biohaven	3.2619 of 5 stars	$14.43 -0.8%	$21.69 +50.3%	-10.9%	$2.17B	N/A	N/A	239	News Coverage Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STTK) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Shattuck Labs (STTK) Competitors

STTK vs. MESO, VERA, SLS, BHVN, and SEPN

How does Shattuck Labs compare to Mesoblast?

Summary

How does Shattuck Labs compare to Vera Therapeutics?

Summary

How does Shattuck Labs compare to SELLAS Life Sciences Group?

Summary

How does Shattuck Labs compare to Biohaven?

Summary

How does Shattuck Labs compare to Septerna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Shattuck Labs (STTK) Competitors

STTK vs. MESO, VERA, SLS, BHVN, and SEPN

How does Shattuck Labs compare to Mesoblast?

Do analysts prefer STTK or MESO?

Which has more risk & volatility, STTK or MESO?

Do institutionals and insiders have more ownership in STTK or MESO?

Which has stronger earnings & valuation, STTK or MESO?

Is STTK or MESO more profitable?

Does the media refer more to STTK or MESO?

Summary

How does Shattuck Labs compare to Vera Therapeutics?

Which has better earnings and valuation, STTK or VERA?

Which has more volatility and risk, STTK or VERA?

Do analysts recommend STTK or VERA?

Do institutionals & insiders have more ownership in STTK or VERA?

Is STTK or VERA more profitable?

Does the media favor STTK or VERA?

Summary

How does Shattuck Labs compare to SELLAS Life Sciences Group?

Do analysts recommend STTK or SLS?

Which has higher earnings and valuation, STTK or SLS?

Does the media refer more to STTK or SLS?

Is STTK or SLS more profitable?

Which has more volatility & risk, STTK or SLS?

Do institutionals and insiders believe in STTK or SLS?

Summary

How does Shattuck Labs compare to Biohaven?

Do analysts rate BHVN or STTK?

Does the media prefer BHVN or STTK?

Is BHVN or STTK more profitable?

Which has more volatility & risk, BHVN or STTK?

Do institutionals & insiders hold more shares of BHVN or STTK?

Which has better earnings & valuation, BHVN or STTK?

Summary

How does Shattuck Labs compare to Septerna?

Do analysts recommend STTK or SEPN?

Which has better valuation and earnings, STTK or SEPN?

Does the media refer more to STTK or SEPN?

Is STTK or SEPN more profitable?

Which has more volatility & risk, STTK or SEPN?

Do institutionals and insiders have more ownership in STTK or SEPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STTK vs. The Competition

Shattuck Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools